Skip to main content

NOVEL DRUG RECONSTITUTION SYSTEMS - CURRENT MARKET LANDSCAPE

 

Over the years, novel drug reconstitution systems have been widely adopted in the healthcare sector, owing to the numerous benefits offered by these products. During our research, we identified over 55 novel drug reconstitution systems, including prefilled syringes, cartridges and infusion bags being manufactured to ease the reconstitution of drugs packaged in containers.

To order this detailed 180+ page report, please visit this - https://www.rootsanalysis.com/reports/drug-reconstitution-systems-market.html

 

Graphical user interface, application Description automatically generated

 

Majority of the companies (32%) engaged in this domain are very large players. Examples of such companies include (in alphabetical order, established after 1900) Baxter, Fresenius Kabi, ICU Medical, Shandong Pharmaceutical Glass, Terumo, Vetter Pharma and West Pharmaceutical Services. This is followed by the share of mid-sized players (29%) in this domain. Prominent examples of mid-sized players include (in alphabetical order, established after 2000) ADIENNE, Kapsam, and Taian Youlyy Industrial. Further, majority of the companies (47%) engaged in this domain are located in Europe, particularly in Germany. This is followed by the players based in Asia-Pacific region with Japan and South Korea being the most prominent countries. Within North America, US emerged as the leading region, with the presence of seven companies.

 

As can be observed in the figure, majority of the prefilled syringes (37.5%) and infusion bags (28.6%) are dual chamber systems. On the other hand, around 18% of the infusion bags are multi chambered. Further, the cartridges are available with single and dual chambers, which make the administration of lyophilized drugs possible in an efficient and convenient manner. Further, most of the prefilled syringes have capacity of 1-2.5 mL.

 

Graphical user interface Description automatically generated with medium confidence

As can be observed in the figure, plastic (57%) emerged as the most popular type of container fabrication material used in novel drug reconstitution systems. Ethylene vinyl acetate (EVA) emerged as the preferred plastic type used for the fabrication of majority (41%) of novel drug reconstitution system containers. EVA is a hydrophobic polymer that offers great flexibility and does not require solvents for drug delivery. Polypropylene, having demonstrated good impact strength and improved resistance to moisture, is the next popular material used in the manufacturing of novel drug reconstitution systems.

To Request for sample - https://www.rootsanalysis.com/reports/drug-reconstitution-systems-market/request-sample.html

As can be seen in the figure, Nipro and SCHOTT-KAISHA emerged as the most prominent players in this domain, developing four novel drug reconstitution systems each. It is worth mentioning that Nipro offers all the three types of novel drug reconstitution systems, namely- dual chamber prefilled syringe (2), dual chamber cartridge (1), and dual chamber infusion bag.

You may also be interested in the following titles:

1.     1DNA-Encoded Libraries: Platforms and Services Market, 2020–2030

2.     Antibody Contract Manufacturing Market, 2020 – 2030

3.     Global Autoinjectors Market, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more